{"id":"W3006140059","doi":"10.1007/s00280-020-04038-8","title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nexen (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Tolerability; Trametinib; Dosing; Medicine; Rash; Adverse effect; Internal medicine; Mucositis; Oncology; Pharmacology; Toxicity; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515739,0.001215665,0.00174003,0.0003233224,0.0003521714,0.0006372929,0.0007331678,0.0006977916,0.00225615],"category_scores_gemma":[0.0008340842,0.0004941172,0.001066295,0.0003841591,0.0006116585,0.0006789824,0.0003303479,0.003546081,0.0004901198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009754926,"about_ca_system_score_gemma":0.001300858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000534242,"about_ca_topic_score_gemma":0.002201883,"domain_scores_codex":[0.9995333,0.0002215808,0.00003117803,0.00008144145,0.00005174286,0.00008081631],"domain_scores_gemma":[0.9993874,0.0001086743,0.0001757026,0.00006546271,0.00003742716,0.0002252895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6288686,0.1075686,0.01162797,0.001015987,0.00164992,0.0004080941,0.0005184318,0.005263506,0.06890313,0.0002120083,0.003310263,0.1706534],"study_design_scores_gemma":[0.4575975,0.5121949,0.01782225,0.00004155902,0.0005349897,0.0003960406,0.00005938822,0.002273317,0.007045433,0.0001484943,0.001856104,0.00003002968],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972365,0.0006350664,0.0002268285,0.000145651,0.00003856307,0.0008923645,0.0002055478,0.00003852139,0.0005809776],"genre_scores_gemma":[0.9957693,0.0005012897,0.001051349,0.0002817104,0.00006687113,0.0007425604,0.0006798885,0.0000105651,0.0008965803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00225615,"threshold_uncertainty_score":0.008016109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01414950799063345,"score_gpt":0.2872376165837309,"score_spread":0.2730881085930975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}